Treatment of Type II diabetes mellutis with amylin agonists

Details Treatment of Type II diabetes mellutis with amylin agonists Treatment of Type II diabetes mellutis with amylin agonists

1995-06-07

2000-11-07

Woodward, Michael P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 4, 514 21, A61K 3810, A61K 3823

Patent

active

061437182

ABSTRACT:
Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.

REFERENCES:
patent: 5124314 (1992-06-01), Cooper
patent: 5175145 (1992-12-01), Cooper
patent: 5234906 (1993-08-01), Young et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5281581 (1994-01-01), Cooper et al.
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5376638 (1994-12-01), Young et al.
patent: 5686411 (1997-11-01), Gaeta et al.
Kolterman et al., "Infusion of Amylin Agonist AC-0137, Reduces Postprandial Hyperglycemia in Subjects with Type I Diabetes" Clinical Research 42 (1), pp 87A, Feb. 12, 1994.
Deems, et al. Biochem. Biophys. Res. Commun. 181:116-120 (1991).
Kanatsuka, et al., FEBS Letters 259:199-201 (1989).
Young, et al. J. Cell Biochm. 55S:12-18 (1994).
Alam, et al. Biochem. Biophys. Res. Commun. 179:134-139 (1991).
Beaumont, et al. Mol. Pharmacol. 44:493-497 (1993).
Brain, et al. Eur. J. Pharmacol. 183:2221 (1990).
Broderick, et al. Biochem. Biophys. Res. Commun. 177:932-938 (1991).
Chance, et al. Brain Res. 539:352-354 (1991).
Cooper, et al. Proc. Natl. Acad. Sci. USA 85:7763-7766 (1988).
Cooper, et al. Proc. Natl. Acad. Sci. 85:7763-7766 (1988).
Cooper, et al. Proc. Natl. Acad. Sci. 84:8628-8632 (1987).
Deems, et al. Biochem. Biophys. Res. Commun. 174:716-720 (1991).
Frontoni, et al. Diabetes 40:568-573 (1991).
Gedulin, et al. Biochem. Biophys. Res. Commun. 180:782-789 (1991).
Gill, et al. Life Sciences 48:703-710 (1991).
Gomez-Foix, et al. Biochem J. 276:607-610 (1991).
Hartter, et al. Diabetologia 34:52-54 (1991).
Huang, et al. Hypertension 19:I-101-I-109 (1991).
Koda, et al. The Lancet 339:1179-1180 (1992).
Koopmans, et al. Diabetologia 34:218-224 (1991).
Leighton, Diabetologia 35:801-802 (1992).
Leighton and Cooper Nature, 335:632-635 (1988).
Lupien and Young Diabetes Nutrition and Metabolism--Clinical and Experimental vol. 6(1), pp. 13-18 (1993).
Moore, et al. Biochem. Biophys. Res. Commun. 179:1-9 (1991).
Moyses and Kolterman Amylin--A New Approach to Diabetes Therapy (May 1995).
Ogawa, et al. J. Clin. Invest. 85:973-976 (1990).
Ohsawa, et al. Biochem. Biophys. Res. Commun. 160:961-967 (1989).
Phillips, et al. J Nucl Med, 33:1496-1500 (1992).
Rink, et al. Trends Pharmacol. Sci. 14:113-118 (1993).
Roden, et al. Diabetologia 35:116-1120 (1992).
Sanke, et al. Diabetologia 34:129-132 (1991).
Silvestre, et al. Reg. Pept. 31:23-31 (1991).
Stephens, et al. Diabetes 40:395-400 (1991).
The Diabetes Control and Complications Trial Research Group, N. Eng. J. Med. 329:977 (1993).
Young, et al. Diabetologia 38:642-648 (Jun. 1995).
Young, et al. FEBS Letts. 281:149-151 (1991).
Young et al. Mol. Cell. Endocrinol. 84:R1-R5 (1992).
Zaidi, et al., J. Bone Mineral Res. 5 (Suppl. 2) S76 (1990).
Young, et al. J. Cell Biochm. 55s:12-18 (1994).

Affiliated with

Also associated with

Rating

Treatment of Type II diabetes mellutis with amylin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of Type II diabetes mellutis with amylin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Type II diabetes mellutis with amylin agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1641116